Possible fifth case of brain infection linked to Tysabri

Share this article:
A possible fifth case of a rare and deadly brain infection linked to the multiple sclerosis (MS) drug Tysabri has been reported to federal regulators, The Wall Street Journal reported today.
The case was reported May 16 through the FDA's Adverse Event Reporting System, which collects reports of possible drug reactions from doctors and drug makers.
An FDA spokeswoman told the newspaper that these reports don't represent confirmed cases.
The fifth possible case was reported by an unnamed health professional and concerns a female patient whose age is undisclosed. No other details of her condition were available, the newspaper report said.
Share this article:

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.